ArticleThe Journal of general physiology2021

Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation.

Lorenzo R Sewanan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.